Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.

Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman SM, Kurzrock R.

Clin Cancer Res. 2017 Aug 15;23(16):4716-4723. doi: 10.1158/1078-0432.CCR-17-0454. Epub 2017 Apr 18.

2.

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.

Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F.

Clin Cancer Res. 2017 Jul 15;23(14):3657-3666. doi: 10.1158/1078-0432.CCR-16-2592. Epub 2017 Jan 17.

3.

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.

Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, Perol M, Oxnard GR, Kosco K, Croucher P, Samuelsz E, Vibat CR, Guerrero S, Geis J, Berz D, Mann E, Matheny S, Rolfe L, Raponi M, Erlander MG, Gadgeel S.

J Thorac Oncol. 2016 Oct;11(10):1690-700. doi: 10.1016/j.jtho.2016.05.035. Epub 2016 Jul 25.

4.

ApoStream(™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood.

Gupta V, Jafferji I, Garza M, Melnikova VO, Hasegawa DK, Pethig R, Davis DW.

Biomicrofluidics. 2012 Jun 27;6(2):24133. doi: 10.1063/1.4731647. Print 2012 Jun.

5.

Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression.

Zigler M, Villares GJ, Dobroff AS, Wang H, Huang L, Braeuer RR, Kamiya T, Melnikova VO, Song R, Friedman R, Alani RM, Bar-Eli M.

Cancer Res. 2011 May 15;71(10):3494-504. doi: 10.1158/0008-5472.CAN-10-3555. Epub 2011 Apr 5.

6.

Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.

Villares GJ, Zigler M, Dobroff AS, Wang H, Song R, Melnikova VO, Huang L, Braeuer RR, Bar-Eli M.

Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):626-31. doi: 10.1073/pnas.1006886108. Epub 2010 Dec 27.

7.

CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma.

Melnikova VO, Dobroff AS, Zigler M, Villares GJ, Braeuer RR, Wang H, Huang L, Bar-Eli M.

PLoS One. 2010 Aug 27;5(8):e12452. doi: 10.1371/journal.pone.0012452.

8.

Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis.

Melnikova VO, Balasubramanian K, Villares GJ, Dobroff AS, Zigler M, Wang H, Petersson F, Price JE, Schroit A, Prieto VG, Hung MC, Bar-Eli M.

J Biol Chem. 2009 Oct 16;284(42):28845-55. doi: 10.1074/jbc.M109.042150. Epub 2009 Aug 24.

9.

Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43.

Villares GJ, Dobroff AS, Wang H, Zigler M, Melnikova VO, Huang L, Bar-Eli M.

Cancer Res. 2009 Aug 15;69(16):6730-7. doi: 10.1158/0008-5472.CAN-09-0300.

10.

Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma.

Dobroff AS, Wang H, Melnikova VO, Villares GJ, Zigler M, Huang L, Bar-Eli M.

J Biol Chem. 2009 Sep 18;284(38):26194-206. doi: 10.1074/jbc.M109.019836. Epub 2009 Jul 24.

11.

Inflammation and melanoma metastasis.

Melnikova VO, Bar-Eli M.

Pigment Cell Melanoma Res. 2009 Jun;22(3):257-67. doi: 10.1111/j.1755-148X.2009.00570.x. Epub 2009 Apr 8. Review.

PMID:
19368690
12.

Emerging roles of PAR-1 and PAFR in melanoma metastasis.

Melnikova VO, Villares GJ, Bar-Eli M.

Cancer Microenviron. 2008 Dec;1(1):103-11. doi: 10.1007/s12307-008-0002-7. Epub 2008 Feb 20.

13.

Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry.

Mourad-Zeidan AA, Melnikova VO, Wang H, Raz A, Bar-Eli M.

Am J Pathol. 2008 Dec;173(6):1839-52. doi: 10.2353/ajpath.2008.080380. Epub 2008 Nov 6.

14.

Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.

Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli M.

Cancer Res. 2008 Nov 1;68(21):9078-86. doi: 10.1158/0008-5472.CAN-08-2397.

15.

Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape.

Zigler M, Villares GJ, Lev DC, Melnikova VO, Bar-Eli M.

Am J Clin Dermatol. 2008;9(5):307-11. Review.

PMID:
18717605
16.

Searching for the Achilles' heel of melanoma cells: new treatment modalities.

Melnikova VO, Bar-Eli M.

Pigment Cell Melanoma Res. 2008 Oct;21(5):505-6. doi: 10.1111/j.1755-148X.2008.00493.x. Epub 2007 Aug 15. No abstract available.

PMID:
18713130
17.

Transcriptional control of the melanoma malignant phenotype.

Melnikova VO, Bar-Eli M.

Cancer Biol Ther. 2008 Jul;7(7):997-1003. Epub 2008 Jun 30. Review.

PMID:
18698165
18.

P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer.

Benjamin CL, Melnikova VO, Ananthaswamy HN.

Adv Exp Med Biol. 2008;624:265-82. doi: 10.1007/978-0-387-77574-6_21. Review.

PMID:
18348463
19.

Models and mechanisms in malignant melanoma.

Benjamin CL, Melnikova VO, Ananthaswamy HN.

Mol Carcinog. 2007 Aug;46(8):671-8. Review.

PMID:
17570501
20.

ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis.

Schwartz B, Shoseyov O, Melnikova VO, McCarty M, Leslie M, Roiz L, Smirnoff P, Hu GF, Lev D, Bar-Eli M.

Cancer Res. 2007 Jun 1;67(11):5258-66.

21.

Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo.

Schwartz B, Melnikova VO, Tellez C, Mourad-Zeidan A, Blehm K, Zhao YJ, McCarty M, Adam L, Bar-Eli M.

Oncogene. 2007 Jun 14;26(28):4049-58. Epub 2007 Jan 15.

PMID:
17224907
22.

Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.

Melnikova VO, Bar-Eli M.

Pigment Cell Res. 2006 Oct;19(5):395-405. Review.

PMID:
16965268
23.
24.

Fate of UVB-induced p53 mutations in SKH-hr1 mouse skin after discontinuation of irradiation: relationship to skin cancer development.

Melnikova VO, Pacifico A, Chimenti S, Peris K, Ananthaswamy HN.

Oncogene. 2005 Oct 27;24(47):7055-63.

PMID:
16007135
25.

Cellular and molecular events leading to the development of skin cancer.

Melnikova VO, Ananthaswamy HN.

Mutat Res. 2005 Apr 1;571(1-2):91-106. Review.

PMID:
15748641
26.

Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines.

Melnikova VO, Bolshakov SV, Walker C, Ananthaswamy HN.

Oncogene. 2004 Mar 25;23(13):2347-56.

PMID:
14743208
27.

Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase.

Melnikova VO, Santamaria AB, Bolshakov SV, Ananthaswamy HN.

Oncogene. 2003 Sep 4;22(38):5958-66.

PMID:
12955074
28.

Effects of glutathione peroxidase and catalase on hemolysis and methemoglobin modifications induced by photooxidized psoralen.

Lysenko EP, Melnikova VO, Andina ES, Wunderlich S, Pliquett F, Potapenko AY.

J Photochem Photobiol B. 2000 Jul;56(2-3):187-95.

PMID:
11079480
29.
30.

Photodynamic properties of meta-tetra(hydroxyphenyl)chlorin in human tumor cells.

Melnikova VO, Bezdetnaya LN, Potapenko AY, Guillemin F.

Radiat Res. 1999 Oct;152(4):428-35.

PMID:
10477920
31.

Subcellular localization of meta-tetra (hydroxyphenyl) chlorin in human tumor cells subjected to photodynamic treatment.

Melnikova VO, Bezdetnaya LN, Bour C, Festor E, Gramain MP, Merlin JL, Potapenko AYa, Guillemin F.

J Photochem Photobiol B. 1999 Apr;49(2-3):96-103.

PMID:
10392459

Supplemental Content

Loading ...
Support Center